Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company

Kinnate Biopharma Announces Restructuring and Job Cuts Amid Financial Pressures

Fineline Cube Sep 20, 2023

US-based Kinnate Biopharma Inc., (NASDAQ: KNTE), a company dedicated to the development of small-molecule cancer...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates

Fineline Cube Sep 20, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced receiving...

Company Drug

Pfizer’s Cibinqo and Everest Medicines’ Cefepime-Taniborbactam Selected for Priority Reviews by CDE

Fineline Cube Sep 20, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that Pfizer’s (NYSE: PFE)...

Company Drug

EMA’s CHMP Supports Gilead’s Veklury for COVID-19 Patients with Hepatic Impairment

Fineline Cube Sep 20, 2023

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...

Company Deals

Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors

Fineline Cube Sep 20, 2023

Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...

Policy / Regulatory

NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion

Fineline Cube Sep 20, 2023

The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug...

Company Drug

FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted priority review status to an indication...

Company Deals

Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals

Fineline Cube Sep 20, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into...

Company Drug

Astellas Pharma’s Xtandi NDA for mHSPC Treatment Accepted by China’s CDE

Fineline Cube Sep 20, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Drug

Pfizer’s Litfulo Earns EU Approval as First Treatment for Severe Alopecia Areata in Teens

Fineline Cube Sep 20, 2023

Pfizer (NYSE: PFE) has been granted registration authorization by the European Commission (EC) for Litfulo...

Company Deals

Tianjin Century Kangtai Biomedical Raises Hundreds of Millions in Series A+ and B Financings

Fineline Cube Sep 20, 2023

Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of...

Company Drug

Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial

Fineline Cube Sep 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from...

Company Drug

Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study

Fineline Cube Sep 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine

Fineline Cube Sep 20, 2023

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing...

Company Deals

Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion

Fineline Cube Sep 20, 2023

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with...

Company Deals

Cure Genetics and Frametact Ltd Partner on AAV Vectors for Neurological Diseases

Fineline Cube Sep 19, 2023

Suzhou-based Cure Genetics has entered into a collaboration and licensing agreement with Hong Kong’s Frametact...

Company Drug

Caliway Biopharmaceuticals’ CBL-514 Achieves Milestones in Dercum’s Disease Trial

Fineline Cube Sep 19, 2023

Taiwan-based Caliway Biopharmaceuticals, a specialist in medical aesthetics and inflammatory medicine, has announced that its...

Company Deals

BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion

Fineline Cube Sep 19, 2023

Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative...

Company Deals

Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round

Fineline Cube Sep 19, 2023

China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million...

Company Medical Device

MicroPort MedBot’s SkyWalker Robot Approved for Orthopedic Surgery by NMPA

Fineline Cube Sep 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Posts pagination

1 … 416 417 418 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.